Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

lutetium Lu 177 rsopatamab tetraxetan

A radioimmunoconjugate consisting of rosopatamab, a humanized monoclonal antibody (MoAb) against the external domain of the prostate-specific membrane antigen (PSMA) that is linked, via the chelating agent, dodecanetetraacetic acid (DOTA), to the beta-emitting radioisotope lutetium Lu 177, with potential antineoplastic activity and imaging activity during single-photon emission computerized tomography/computerized tomography (SPECT/CT). Upon administration, lutetium Lu 177 rosopatamab tetraxetan binds to PSMA expressed on certain tumor cells. Upon binding and internalization, this radioconjugate specifically delivers a cytotoxic dose of beta radiation to PSMA-expressing cells. PSMA is overexpressed in the malignant prostate and its metastases.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:177Lu-DOTA-TLX591
DOTA-HUJ-591 LU-177
lutetium Lu 177 rosopatamab
lutetium Lu 177-DOTA-rosopatamab
lutetium Lu 177-DOTA-TLX591
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search